Genmab | GEN - Operating Expenses


Genmab reported DKK798M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Almirall EUR 517.4M 32K Dec/2025
Amarin USD 51.48M 113K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
argenx SE USD 904M 10.57M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Demant DKK 9.63B 241M Dec/2025
Exelixis USD 359.47M 3.28M Mar/2026
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GN Store Nord DKK 2.16B 1.94B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.09B 687M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
UCB EUR 2.96B 196M Dec/2025